[Medical therapy of heart and lung diseases. Effects on the respective other organ].
Many patients suffer from both heart and lung diseases. The choice of medical drugs should not only be driven by the clinical and prognostic effects on the target organ but should also be selected based on the effects on the respective other organ. Beta blockers and statins have both beneficial and harmful effects on the respiratory system. Angiotensin-converting enzyme (ACE) inhibitors and amiodarone can cause severe lung damage. Low-dose thiazides and calcium antagonists are first-line medications in hypertensive asthma patients but beta blockers should be avoided. Theophyline should be used with caution in patients with known cardiac disease. Glucocorticosteroids can cause cardiovascular symptoms while the phosphodiesterase inhibitor roflumilast appears to have no relevant cardiovascular side effects. Anticholinergic drugs have both favorable and unfavorable cardiovascular (side) effects. Short-acting beta-2 sympathomimetic drugs (SABA) and macrolides in particular can trigger arrhythmia and some SABAs are associated with a higher incidence of myocardial infarction. Detailed knowledge of the effects of drugs used for the treatment of lung and heart diseases on the respective other organ and the associated complications and long-term effects are essential in providing optimal medical care to the many patients who present with both respiratory and cardiovascular diseases.
Klinik für Kardiologie, Angiologie und Internistische Intensivmedizin, Krankenhaus Bethanien, Moers, Deutschland.
S
S
Möhlenkamp
G
G
Weinreich
T
T
Neumann
T
T
Voshaar
H
H
Teschler
D002317:Cardiovascular Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006331:Heart Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D019141:Respiratory System Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
D002317:Cardiovascular Agents; D019141:Respiratory System Agents